Gastric Cancer Prognosis and Survival: Evaluating Clinical Stages and Key Prognostic Factors

Gastric cancer is one of the most common malignant neoplasms in the digestive system and represents a significant challenge in clinical practice due to its late diagnosis and variable prognosis. The stomach cancer life expectancy and gastric cancer survival of patients depend largely on the clinical stage at the time of diagnosis. As we advance in understanding the factors influencing gastric cancer prognosis, it is crucial for physicians to stay informed about the latest research and developments in this field.

In the early stages of gastric cancer, surgery remains the only curative treatment, with five-year survival rates exceeding 95% [1]. However, most patients are diagnosed at advanced stages, where the combination of neoadjuvant chemotherapy, targeted therapy, and immunotherapy becomes the primary approach [2]. The identification of inflammatory and genetic biomarkers, such as the recently developed inflammatory biomarkers model, has proven useful in predicting prognosis and guiding management strategies [3].

The use of advanced imaging techniques, such as magnetic resonance imaging (MRI), has improved clinicians' ability to assess treatment response and predict prognosis in patients with gastric cancer [4]. Additionally, the expression of certain genes and proteins, such as NPC1 and IGFL2, has been associated with unfavorable prognosis, underscoring the importance of molecular characterization in evaluating gastric cancer [5][6].

In conclusion, the prognosis and survival of gastric cancer are intrinsically linked to the clinical stage at the time of diagnosis. The integration of new diagnostic and therapeutic tools, along with a personalized approach based on biomarkers, holds the promise of improving outcomes for patients. Ongoing research and clinical application of these advances are essential to optimize the management of gastric cancer and enhance the life expectancy of patients.

Referencias

• [1] Progress in the treatment of advanced gastric cancer
• [2] Development and validation of an inflammatory biomarkers model to predict gastric cancer prognosis: a multi-center cohort study in China
• [3] Upregulation of NPC1 and its association with poor prognosis in gastric cancer
• [4] The role of MRI in the diagnosis and treatment of gastric cancer
• [5] IGFL2 expression and surgical volume: Independent predictors of survival in gastric cancer

Created 13/1/2025